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Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancers, and currently
two vaccines protecting against these types are available1. In a previous paper, we estimated
the  long-term  effect  of  HPV  vaccination  on  the  risk  of  cervical  cancer  in  the  French
population  using  mathematical  modeling2.  Several  vaccination  scenarios  were  tested,
including different vaccination coverage rates of females alone or in conjunction with males.
In the first scenario, which is based on the vaccination campaign initiated in France in 2007,
30% of females aged 14 to 19 years were vaccinated annually, resulting in a 60% cumulative
vaccination coverage rate among 14 to 19 year old females 6 years after the beginning of the
vaccination campaign. A catch-up program was also included with an annual vaccination rate
of 10% among females aged 20 to 24 years.
Using this scenario, the model predicted an 83% reduction in cervical cancer incidence 50
years after vaccination initiation.  The following scenarios were also considered: extending
vaccination: (1) to males, (2) to females under 14; and scenarios with (3) vaccination among
14 to 24 year-old females (annual rate of 80%), (4) vaccination among 14 to 24 year-old
females and males (annual rate of 80%). Greater reductions in cervical cancer incidence of
92% to 98% were predicted.
Since the publication of this paper, new vaccination coverage data have become available in
France3.  The  aim of  the  present  paper  is  to  estimate  the  impact  of  HPV vaccination  on
cervical  cancer  incidence  and mortality  in  France  given the  current  vaccination  coverage
using the same method. This method was derived from the mathematical theory of epidemics
developed by Kermack and McKendricks in 19274. In recent decades,  extensions based on
dynamic  models  have  been  developed  to  assess  HPV  vaccination  strategies5. The
mathematical  model that  we developed consists  of a  system of differential  equations  that
simulate  the  spread  of  HPV  infection  and  the  progression  to  cervical  cancer.  This
transmission  dynamic  model  simulates  the  transitions  from  the  three  states:  susceptible,
infected and diseased4,6, and takes into account heterosexual transmission of HPV 16/18. The
model is stratified on vaccine status (vaccinated /not vaccinated), age (14 to 19 and 5-year age
groups from 20 to 84), and sexual activity based on the number of sexual partners in the last
12 months (0, 1, 2-3 or 4+ partners). Vaccination coverage was measured by the annual rate
of vaccination. For more details about the complete list of parameters, calibration details, and
discussion of model structure, see Ribassin-Majed et al.2.
The vaccination scenarios analyzed are presented in Table 1. The first scenario is based on the
present vaccination coverage in France, which is restricted to females aged 14 to 19, with a
cumulative vaccination coverage rate of 40%. In the second hypothetical scenario, males aged
14 to 19 are also vaccinated with the same 40% cumulative vaccination coverage rate. In
scenarios 3 and 4, a coverage rate of 50% is assumed, respectively among females alone and
among both males and females, with a 5% coverage catch-up program for individuals aged 20
to 24 years. In scenario 5, vaccination of females less than 14 years of age is considered with
a coverage rate of 46%, which is based on the hepatitis B vaccination coverage rate observed
in France. In our model, individuals who enter the model at age 14 or younger are assumed to
not be sexually active. Scenario 5 assumes that 46% of females entering the study are already
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protected by the vaccine and cannot be infected. The predictions at 20 and 50 years following
vaccination initiation are studied to evaluate the theoretical impact of vaccine coverage on the
reduction of cervical cancer incidence causally associated with HPV 16/18.
When vaccination against infection is available, the spread of the epidemic depends on the
vaccination coverage, and there is a threshold coverage beyond which the epidemic dies out.
We  have  shown  previously  that  a  time  lapse  of  100  years  is  sufficient  to  observe  the
equilibrium of  the  model7.  Thus,  we present  also  the  predictions  at  100 years  following
vaccination initiation.
Results
Our model predicts  a 48% reduction in cervical  cancer incidence and a 27% reduction in
cervical cancer mortality 50 years following vaccination initiation on the basis of the current
vaccination coverage rate (Table 1). These results are based on the hypothesis of constant
vaccination coverage over a period of 50 years. Given that not all women with cervical cancer
die from the disease and that the effect of vaccination on mortality is generally observed later
than the effect on incidence, the impact of vaccination on cervical cancer mortality is much
less pronounced compared to that on cervical cancer incidence.
Vaccinating males with the same coverage rate as that of females (scenario 2) would reduce
the incidence  of cervical  cancer  after  50 years  by an additional  14% and reduce cervical
cancer mortality by an additional 7%, from a reduction of 27% to a reduction of 34%.
The analysis of scenarios 3 and 4 showed a substantially greater reduction in cervical cancer
incidence  compared  to  scenarios  1  and  2.  If  vaccinations  are  restricted  to  only  females
(scenario 3), a 65% reduction in cervical cancer incidence is expected 50 years after initiation
of vaccination, and the additional vaccination of males (scenario 4) leads to a 78% reduction
in cervical cancer incidence after 50 years.
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The  reduction  in  cervical  cancer  incidence  estimated  by  scenario  5  is  greater  than  the
reduction estimated by scenario 1, with a 75% reduction in cervical cancer incidence and a
46% reduction in cervical cancer mortality. These reductions in incidence and mortality are
similar to those obtained by scenario 4, where a high vaccination coverage rate is achieved in
both sexes.
In Table 1, reductions in cervical cancer incidence predicted 100 years after the launch of
vaccination are not equal to 100%. The vaccination coverage proposed by scenarios 1 to 3 is
not sufficient to extinguish the epidemic.  In the last  scenario,  vaccination in both genders
leads to a reduction of cervical cancer incidence of 97%, which is close to the disease-free
equilibrium. If more than half of males and females aged 14 to 19 years were vaccinated
against HPV (scenario 4), cervical cancer cases caused by HPV 16/18 would become very
rare. 
Discussion
The incidence of cervical cancer causally associated with HPV 16/18 will be reduced by 48%
after  50  years  if  the  vaccination  coverage  rate  remains  around  40% and continues  to  be
restricted to females. This is less than our previous estimation of an 83% reduction2, because
the observed cumulative vaccination coverage rate of 40% among females aged 14 to 19 is
much less than the 60% hypothesized in our previous analysis. These findings have important
implications for public health and could serve to inform HPV vaccination initiatives.
Targeting younger females could lead to further reductions in cervical cancer incidence after
50 years, as shown by our analysis of vaccinating females less than 14 years of age (scenario
5). In France, the target age for HPV vaccination was recently lowered from 14 years to 11
years of age. Compliance has been shown to be higher among younger girls; thus, this new
schedule could lead to increased vaccination coverage in the future. In France, vaccination
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against hepatitis B is proposed to 11 year old children, and the Health Authority has reported
a vaccination coverage rate of 46%3. 
In  some  countries,  school-based  programs  for  HPV  vaccination  have  achieved  higher
vaccination coverage. In Australia, coverage of 80% has been reached among females and a
large reduction in the incidence of genital warts has already been observed (the quadrivalent
vaccine used also protects  against  genital  warts)8.  However,  the impact of vaccination  on
cervical cancer incidence will be observed in several decades, given the long time lag between
HPV infection and cervical cancer. 
New findings also suggest that HPV vaccination with two doses of vaccine instead of the
recommended three doses is sufficient to ensure protection9. A reduction in the number of
required  doses  would  improve  compliance  with  the  vaccination  schedule.  Expanding  the
vaccination  to  males  would  also  significantly  improve  the  reduction  in  cervical  cancer
incidence and therefore in mortality.
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Table 1: Human Papillomavirus Vaccination scenarios and consequences on HPV 16 and/or
HPV 18 associated cervical cancer incidence and mortality in France
Sex of vaccinated population (scenario number)
Female
(1)
Female & Male
(2)
Female
(3)
Female & Male
(4)
Female
(5)
Age of vaccinated 
population in years
Annual Vaccine coverage†
<14 0% 0% 0% 0% 46%
14 to 19 11% 11% 17% 17% 11%
20 to 24 0% 0% 2.2% 2.2% 0%
Cumulative Vaccine coverage‡
<14 0% 0% 0% 0% 46%
14 to 19 40% 40% 50% 50% 40%
20 to 24 0% 0% 5% 5% 0%
Number of years after 
vaccination initiation
Reduction in cervical cancer incidence*
20 14% 17% 21% 25% 24%
50 48% 62% 65% 78% 75%
100 66% 88% 83% 97% 91%
Reduction in cervical cancer mortality*
20 1% 2% 3% 4% 3%
50 27% 34% 38% 49% 46%
100 44% 66% 61% 83% 74%
† Estimated, used as input for the dynamic modeling.
‡ Proportion of individuals in the age group who received three vaccine doses.
* Compared to no vaccination.
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Abstract for submission
Two vaccines against human papillomavirus (HPV) are available to prevent cervical cancer
and anogenital cancers. Both vaccines protect against HPV types 16 and 18, which cause 70%
of cervical cancers. In a previous paper, we had estimated the efficacy of vaccination against
HPV 16/18 infections to prevent cervical cancer in the French population, using modeling
with  a  dynamic  model  that  simulates  the  transitions  from  the  three  states:  susceptible,
infected, and diseased.
The aim of this short paper is to update our estimation of the impact of HPV vaccination on
cervical cancer incidence and mortality in France based on current vaccination coverage data.
Several vaccination scenarios are evaluated: the current vaccination coverage, hypothetical
scenarios including vaccination of males, and/or different target age groups among females.
The incidence of cervical cancer due to HPV 16/18 would be halved after 50 years if the
vaccine coverage remains around 40% and remains restricted to females 14 to 19 years old. A
larger reduction in cervical cancer incidence is predicted by scenarios including vaccination
of males or vaccinating females before age 14. 
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